The treatment of spinal muscular atrophy in Clinical Center Tuzla
Health professionals from the University Clinical Center Tuzla for the first time applied Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy (SMA). Nusinersen is administered to a newborn patient aged 1.5 months after spinal muscular atrophy was diagnosed by a screening test at birth, and then confirmed by molecular genetic analysis. Spinal muscular atrophy…
Details